KemPharm Receives USAN Approval for “Asalhydromorphone” as Nonproprietary Name for Novel Prodrug Candidate, KP511

CORALVILLE, Iowa, Nov. 06, 2017 (GLOBE NEWSWIRE) — KemPharm, Inc, a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that the United States Adopted Name (USAN) Council approved the use of the nonproprietary name, “Asalhydromorphone (Asal-HM),” for use as the descriptor for the active pharmaceutical ingredient of its opioid-base pain treatment product candidate, KP511.